Two Pediatric Bone Disorders in the Era of Disease Specific Therapies – When to Refer Patients and How to Treat XLH and HPP

Released On
June 21, 2022

Expires On
June 21, 2023

Media Type

Completion Time
60 minutes

Endocrinology, Genetics, Neonatology, Nephrology, Neurology, Pain Management, Pediatrics, Pharmacy, Primary Care, Radiology, Rheumatology, Surgery

Pediatrics, Radiology, Surgery

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by P2P Syncro and Postgraduate Institute for Medicine.

This activity is supported in by an independent education grant from Alexion and Ultragenix.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hour
  • Physician Assistants — 1.0 CE Credit
  • Pharmacists — 1.0 Contact Hour

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of pediatricians in endocrinology, primary care, rheumatology, orthopedics, neurology, radiology, nephrology, neonatology, and other speciaties. Healthcare providers including geneticists and genetic counselors are included.

Program Overview

X-linked hypophosphatemia (XLH) and hypophosphotasia (HPP) are genetic metabolic bone diseases with recent treatment advances. This program will discuss when to refer and how to treat children with XLH or HPP in the era of disease specific therapies.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review pathophysiology, presentation, and diagnosis of hypophosphatasia (HPP) and X-linked hypophosphatemia (XLH) in children.
  • Evaluate the mechanisms, efficacy, and safety of agents approved for the treatment of HPP and XLH
  • Develop personalized strategies for the long-term management of children with HPP and XLH.




Jill H. Simmons, MD

Dr. Jill Simmons is a Professor of Pediatrics in the Ian M. Burr Division of Pediatric Endocrinology and Diabetes at Vanderbilt University Medical Center. She is the founder and director of the Vanderbilt Program for Pediatric Metabolic Bone Disease.

Dr. Simmons is an investigator of clinical trials on novel therapies for metabolic bone diseases in children. She authored numerous publications on the diagnosis and treatment of diseases including hypophosphatasia and X-linked hypophosphatemia. She serves as a regular reviewer for Diabetes Care, Journal of Clinical Endocrinology and Metabolism, Journal of Clinical Investigation, Pediatric Blood and Cancer, and Pediatric Diabetes.


Eric T. Rush, MD

Dr. Eric Rush is a Clinical Geneticist at Children’s Mercy Hospital and an Associate Professor of Pediatrics at the University of Missouri-Kansas City. He is the co-director of the Children’s Mercy Skeletal Dysplasia clinic.

Dr. Rush’s clinical and research interests include hypophosphatasia and X-linked hypophosphatemia, among others. Topics of his publications ranged from molecular characterization, skeletal pathology, to best practice of using novel therapies in rare genetic diseases. Dr. Rush is board certified in Pediatrics, Internal Medicine and Clinical Genetics. He is on the Scientific Advisory Board for the Rare Bone Diseases Alliance.


Physician Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and P2P Syncro. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - UAN JA4008162-9999-22-284-H04-P. Type of Activity: Knowledge

Continuing Physician Assistant Education

Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until June 21, 2023. PAs should only claim credit commensurate with the extent of their participation.


Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Jill Simmons, MD
  • Grant and Research Support: Ultragenix, Amgen, Alexion, all with research support to the institution
  • Speakers Bureau/Honoraria for non-CME: Ultragenix, Alexion
  • Consultant/Advisory Board: Ultragenix, Alexion, Aruvant
Eric Rush, MD
  • Grant and Research Support: Alexion, Ultragenix
  • Speakers Bureau/Honoraria for non-CME: Alexion, BioMarin, Ultrgenix, Inozyme
  • Consultant/Advisory Board: Alexion, BioMarin, Ultragenix, Inozyme, Ipsen, Ascendis
  • Non-mutual funds stock ownership/stock options: Intercept, Spectrum

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.

Certificates will be emailed to the participant.

For Pharmacists: Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

Postgraduate Institute for Medicine (PIM) requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.


This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For CME questions please contact: